Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Panel Backs Efficacy Of BioMarin’s Rare Disease Drug Vimizim

This article was originally published in The Pink Sheet Daily

Executive Summary

Majority of the Endocrinologic and Metabolic Drugs Advisory Committee says effectiveness of elosulfase alfa has been demonstrated and the drug should be approved for all patients with Morquio A syndrome regardless of baseline disease severity.


Related Content

FDA Quietly Consults Patients To Understand Vimizim's Six-Minute Walk Significance
Getting With The PRO-gram: Making Patient-Reported Outcomes Work
FDA Quietly Consults Patients To Understand Six-Minute Walk Significance
BioMarin Tests FDASIA’s Pediatric Voucher Waters With Vimizim Approval
BioMarin’s Vimizim Secures Broad Label In Morquio A Syndrome
Repurposing Leptin (Part 2): It Really Is A One-In-A-Million Drug
Vimizim Panel’s Desire For Quality-Of-Life Data Runs Into Regulatory Reality
Efficacy Endpoint For BioMarin’s Vimizim Faces FDA Panel Scrutiny


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts